ISTA Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Irvine, California. ISTA Pharmaceuticals, Inc. is an ophthalmic pharmaceutical company with products and product candidates for the treatment of inflammation, ocular pain, glaucoma, allergy and dry eye. The Company has three products available for sale in the United States: Xibrom, (bromfenac ophthalmic solution) for the treatment of inflammation and pain following cataract surgery, Istalol, (timolol maleate ophthalmic solution) for the treatment of glaucoma, and Vitrase (hyaluronidase for injection) for use as a spreading agent. The Company also has several product candidates in various stages of development. These include a strong steroid product candidate to treat ocular inflammation, iganidipine to enhance ocular nerve blood flow and a new formulation of latanoprost for the treatment of glaucoma.

Amerifit Brands aims to calm the irritating tickles, hot flashes, and pains that accompany everyday life. The company develops, markets, and distributes a variety of natural, non-prescription products blended from herbs, minerals, pharmaceuticals, and vitamins. Amerifit's brands include AZO and Estroven (women's wellness), Flex Able (joint health), Sootherbs (cough and cold remedies), and Vitaball (children's multivitamin). Its products take a variety of forms, including lozenges, gumballs, gels, and pills. The company's products are primarily sold in chain drug stores and mass market retailers. Amerifit is owned by private equity firm Charterhouse Group and has agreed to be acquired by Martek Biosciences.

GeneFluidics, Inc. develops electrochemical sensor platform for molecular analysis. Its solutions perform bioassays with sensitivity to picogram/ml concentrations for immunoassays and femtomolar concentrations for genetic assays. The company’s products include sensor chip arrays; Proteus, a modular robotic system; and Asklepios, the multi-channel microfluidics cartidge system. Its products are used for human diagnostics, animal health, environmental monitoring, and blood banking applications. The company was incorporated in 2000 and is headquartered in Monterey Park, California.

New Energy Technologies, Inc. was founded in 1998 and is based in Burtonsville, Maryland. New Energy Technologies, Inc., through its subsidiaries, engages in the identification, acquisition, development, and commercialization of alternative energy technologies. It focuses on the development of MotionPower, a technology for capturing the kinetic energy of moving vehicles in order to use this captured energy to generate electricity; and SolarWindow, a technology that enables transparent glass windows to generate electricity by coating their glass surfaces with small solar cells. The company was formerly known as Octillion Corp. and changed its name to New Energy Technologies, Inc. in January 2009.

Ortho-McNeil, a subsidiary of gigantic healthcare company Johnson & Johnson, makes a variety of women's health and contraceptive products. A division of Ortho-McNeil-Janssen Pharmaceuticals, its women's health line is dominated by oral contraceptives, including Ortho-cyclen, Ortho-novum, and Modicon; other products include Ditropan for overactive bladder treatment and yeast infection drug Terazol. Sister company Ortho-McNeil Neurologics was created to hold Ortho-McNeil's central nervous system drugs, including epilepsy treatment Topamax, pain management drug Ultracet, Alzheimer's treatments, and migraine remedies, allowing the company to focus strictly on women's health.

XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California. XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies and other agents to treat inflammatory, autoimmune, infectious, and oncological diseases. The company receives royalties on three approved products: RAPTIVA, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis; LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA, which is approved in the U.S. and Switzerland for the treatment of Crohn's disease. Its products under development include XOMA 052, a monoclonal antibody for the treatment of Type 2 diabetes, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and gout, which is in Phase 1 clinical studies; and XOMA 3AB, a biodefense anti-botulism antibody for the treatment of botulism poisoning. The company's developing products also include HCD122, a human anti-CD40 antagonist antibody for the treatment for B-cell mediated diseases, including malignancies and autoimmune diseases in Phase 1 and Phase 2 clinical trials for various indications. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Genentech, Inc.; UCB Celltech; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Schering-Plough Research Institute; Novartis AG; and Arana Therapeutics Limited.

AVANIR Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California. AVANIR Pharmaceuticals, Inc. focuses on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States and Canada. Its lead product candidate includes Zenviatm, which has completed three Phase III clinical trials for the treatment of pseudobulbar affect; and a Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain. The company also offers Abreva, an over-the-counter product for the treatment of cold sores.

Nutra Pharma Corporation was founded in 2000 and is based in Boca Raton, Florida. Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

Champions Biotechnology, Inc. company was founded in 1985 and is based in Baltimore, Maryland. Champions Biotechnology, Inc., a biotechnology company, engages in the development of advanced preclinical platforms and predictive tumor specific data to enhance the value of oncology drugs in the United States. Its preclinical platform is an approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts) in a manner that preserves the biological characteristics of the original human tumor. The company leverages its preclinical platform to evaluate and develop a portfolio of oncology drug candidates through preclinical trials; and plans to sell, partner or license such drug candidates to pharmaceutical and/or biotechnology companies.Champions Biotechnology provides Personalized Oncology Services to physicians in the field of oncology by establishing and administering expert medical information panels for their patients to analyze medical records and test results; to assist in understanding conventional and experimental options; and to identify and arrange for testing, analysis, and study of the patients cancer tissues. In addition, the company offers personalized Tumorgraft development and drug studies to physicians for evaluating the effects of cancer therapies on their patient's. It offers its platform and tumor specific data to other biotechnology and pharmaceutical companies. The company was formerly known as Champions Sports, Inc. and changed its name to Champions Biotechnology, Inc. in January 2007 as a result of change in its business focus towards biotechnology.

Lab901 is not that college class you flunked. It's a company that develops and manufactures laboratory processing products to increase the efficiency of analytical laboratory testing used for DNA tests and other applications. Lab901's ScreenTape system is disposable a credit-card sized strip patterned with reagents used to process and analyze biological samples such as blood, DNA, and RNA. Lab901 was formed in 2001.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.